A Novel Label-Free Biosensor for Detection of HE4 in Urine Based on Localized Surface Plasmon Resonance and Protein G Directional Fixed

Duan, Ruiqi; Xi, Mingrong

doi:10.1155/2020/8613240

Cited by 11 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the experiments, the FDNM shows a much lower LOD in a complicated sample, which is 10 pg mL -1 , than most other analog LSPRimmunoassay as listed in Table S2. [ [33][34][35][36][37][38][39][40][41][42][43][44][45] The result also presents signi cant discrimination and dynamic detecting range in the complicated saliva samples. Taken together with its quick readout time (less than 15 minutes) and simple operation, it well demonstrated the capability of the FDNM in rapid detection against spike protein of SARS-CoV-2 in saliva.…”

Section: Discussionmentioning

confidence: 84%

Spectral Image Contrast Based Flow Digital Nanoplasmon-metry For Ultrasensitive Antibody Detection

Wang

Kuo

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Gold nanoparticles (AuNPs) have been widely used as local surface plasmon resonance (LSPR) immunoassay for biomolecule sensings. It is primarily based on two conventional methods - absorption spectra and colorimetric. While the low figure of merit (FoM) of the LSPR and high-concentration AuNPs requirement restrict their limit of detection (LOD), which is around ng to μg per mL in antibody detection if there is no other signal or analytes amplification. By now, the improvement of sensitivity has bogged down for years. It also reveals a great challenge of the current LSPR immunoassay in biosensing - pushing the boundary of the current LOD.Results: In this work, we developed a spectral image contrast-based flow digital nanoplasmon-metry(FDNM) to push the LOD boundary. Comparing the scattering image brightness of AuNPs in two neighboring wavelength bands near the LSPR peak, the signal of peak shift is extremely amplified and quickly detected. Introducing the digital analysis, the FDNM provides an ultra-high signal-to-noise ratio and less sample volume requirement. Compared to conventional analog LSPR immunoassay, FDNM has a LOD down to 1 pg mL-1 within only a 15-minute detection time and 500 μL sample volume. Antibody against spike proteins of SARS-CoV-2 in artificial saliva that contained various proteins was also conducted to validate the detection of FDNM in complicated samples. Of the detection, FDNM shows significant discrimination with a LOD of 10 pg mL-1 and a broad dynamic detecting range of five orders of magnitude. Conclusion: Together with the quick readout time and simple operation, this work outstandingly demonstrated the high sensitivity and selectivity of the developed FDNM in rapid antibody detection. The spectral image contrast and digital analysis further provide a new generation LSPR immunoassay of AuNPs.

show abstract

Section: Discussionmentioning

confidence: 84%

Spectral Image Contrast Based Flow Digital Nanoplasmon-metry For Ultrasensitive Antibody Detection

Wang

Kuo

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The array surface plasmon resonance imaging (SPRi) technique, used with a suitable biosensor, appears to be a suitable tool for the determination of CDH12 in blood plasma or serum. SPR and SPRi biosensors enable the determination in blood plasma/serum of commonly used cancer biomarkers such as cancer antigen 125 (CA 125) [11], human epididymis protein 4 (HE 4) [12], and emerging cancer biomarkers such as aromatase [13], as well as numerous other biomarkers including cathepsins B, D, and G [14]. Other types of biosensors are also of great importance.…”

Section: Introductionmentioning

confidence: 99%

Development of an SPRi Test for the Quantitative Detection of Cadherin 12 in Human Plasma and Peritoneal Fluid

Oldak,

Lukaszewski,

Leśniewska

et al. 2023

IJMS

View full text Add to dashboard Cite

A new method for the determination of cadherin 12 (CDH12)—an adhesive protein that has a significant impact on the development, growth, and movement of cancer cells—was developed and validated. The method is based on a biosensor using surface plasmon resonance imaging (SPRi) detection. A quartz crystal microbalance was used to analyze the characteristics of the formation of successive layers of the biosensor, from the linker monolayer to the final capture of CDH12 from solution. The association equilibrium constant (KA = 1.66 × 1011 dm3 mol−1) and the dissociation equilibrium constant (KD = 7.52 × 10−12 mol dm−3) of the anti-CDH12 antibody–CDH12 protein complex were determined. The determined analytical parameters, namely the values determining the accuracy, precision, and repeatability of the method, do not exceed the permissible 20% deviations specified by the aforementioned institutions. The proposed method is also selective with respect to possible potential interferents, occurring in up to 100-fold excess concentration relative to the CDH12 concentration. The determined Limit of Quantification (LOQ = 4.92 pg mL−1) indicates the possibility of performing quantitative analysis in human plasma or peritoneal fluid without the need to concentrate the samples; however, particular attention should be paid to their storage conditions, as the analyte does not exhibit high stability. The Passing–Bablok regression model revealed good agreement between the reference method and the SPRi biosensor, with ρSpearman values of 0.961 and 0.925.

show abstract

“…A simple localized surface plasmon resonance (LSPR) biosensor with silver nanoparticles and the anti-HE4 antibody was developed for marker determination in blood serum [8]. This biosensor was updated for analytical signal enhancement [9]. Protein G is covalently immobilized on the silver nanoparticles, and an anti-HE4 antibody is attached to protein G. Such a biosensor is suitable for the determination of the HE4 marker in urea.…”

Section: Introductionmentioning

confidence: 99%

An SPRi Biosensor for Determination of the Ovarian Cancer Marker HE4 in Human Plasma

Szymańska

Łukaszewski

Żelazowska-Rutkowska

et al. 2021

Sensors

View full text Add to dashboard Cite

Human epididymis protein 4 (HE4) is an ovarian cancer marker. Various cut-off values of the marker in blood are recommended, depending on the method used for its determination. An alternative biosensor for HE4 determination in blood plasma has been developed. It consists of rabbit polyclonal antibody against HE4, covalently attached to a gold chip via cysteamine linker. The biosensor is used with the non-fluidic array SPRi technique. The linear range of the analytical signal response was found to be 2–120 pM, and the biosensor can be used for the determination of the HE4 marker in the plasma of both healthy subjects and ovarian cancer patients after suitable dilution with a PBS buffer. Precision (6–10%) and recovery (101.8–103.5%) were found to be acceptable, and the LOD was equal to 2 pM. The biosensor was validated by the parallel determination of a series of plasma samples from ovarian cancer patients using the Elecsys HE4 test and the developed biosensor, with a good agreement of the results (a Pearson coefficient of 0.989). An example of the diagnostic application of the developed biosensor is given—the influence of ovarian tumor resection on the level of HE4 in blood serum.

show abstract

A Novel Label-Free Biosensor for Detection of HE4 in Urine Based on Localized Surface Plasmon Resonance and Protein G Directional Fixed

Cited by 11 publications

References 21 publications

Spectral Image Contrast Based Flow Digital Nanoplasmon-metry For Ultrasensitive Antibody Detection

Spectral Image Contrast Based Flow Digital Nanoplasmon-metry For Ultrasensitive Antibody Detection

Development of an SPRi Test for the Quantitative Detection of Cadherin 12 in Human Plasma and Peritoneal Fluid

An SPRi Biosensor for Determination of the Ovarian Cancer Marker HE4 in Human Plasma

Contact Info

Product

Resources

About